[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extracellular-vesicles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extracellular-vesicles":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,72,110,134,164,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622308","the-effect-of-consumed-berries-on-extracellular-vesicle-signalling-in-the-body-100622308",false,"NCT07381933","The Effect of Consumed Berries on Extracellular Vesicle Signalling in the Body","NutriEV RCT","Inclusion Criteria:\n\n* Age 18-50\n* Individuals of all heights and weights and both female and male sexes are accepted\n* Written informed consent is required from all study participants\n* Use of probiotics is allowed, but the usage will be reported\n\nExclusion Criteria:\n\n* Known or suspected allergy to cloudberries or lingonberries\n* Current dermatological or gastrointestinal conditions requiring treatment or interfering the sampling\n* Renal failure\n* Type 1 or type 2 diabetes\n* Pregnancy\n* Immunodeficiency or any condition affecting the immune system, e.g. chronic viral infection\n* Ongoing antibiotic treatment or antibiotic treatment within the past 3 months\n* Immunosuppressive medication or other medication that can be influenced by the intervention",true,"ALL","18 Years","50 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study examines how berry consumption influences the signaling and distribution of extracellular vesicles (EVs) in the human body. EVs are small bilipid-layered nanoparticles released by cells. EVs carry proteins, lipids, and genetic material, and play a key role in cell-to-cell communication. The composition of EVs reflects the state of their cells of origin, and EVs can affect other cells by delivering their biological contents. EVs offer significant potential for both diagnostics and new therapies.\n\nRecent research has shown that EVs can be found in blood, urine, sweat, and can even cross biological barriers such as the blood-brain barrier and placenta. Many living organisms, including mammalian cells, bacteria, and plants, release EVs. Berries such as cloudberries and lingonberries have demonstrated positive effects on gut microbiota and metabolism, supporting digestive and metabolic health.\n\nIn this study, a nutritional intervention will be conducted to investigate the effects of berry consumption on extracellular vesicle signaling of human cells and the gut microbiota, as well as the biodistribution of berry-derived vesicles in the human body.",[28,29],"Healthy","Extracellular Vesicles",[31],"extracellular vesicles","RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2026-01-23",{"date":40,"type":22},"2026-12-31",{"name":42,"class":43},"University of Oulu","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100624059","phase-1-study-on-the-safety-and-efficacy-of-intratympanic-injection-of-small-extracellular-vesicles-derived-from-mesenchymal-stem-cells-in-severe-and-profound-sudden-sensorineural-hearing-loss-100624059","NCT07404709","Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Clinical Phase I and IIa Trials of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n1. Sudden unilateral hearing loss that occurs within 72 hours, with a decrease of at least 30 decibels in at least 3 frequency ranges compared to the healthy ear, and an average pure tone threshold of ≥ 65 decibels.\n2. Enrollment must be completed within 7 days after the onset of sudden deafness.\n3. Men or women aged 18 to 65\n4. Not treated in any other hospital and not taking any treatment medication on one's own\n5. Be able to understand the trial protocol and undergo regular follow-up visits and check-ups\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. With a history of chronic ear diseases, ear surgery, autoimmune hearing loss or a confirmed diagnosis of Meniere's syndrome in the past\n3. Having received steroid treatment for any reason within the past 30 days\n4. There are autoimmune diseases or chronic inflammatory diseases.\n5. Severe damage to liver and kidney functions\n6. Patients with a previous history of cerebral hemorrhage or those currently taking anticoagulant medications\n7. Other cases in which the researchers judged the candidates to be unsuitable for inclusion","65 Years",{"count":54,"type":22},9,[56,57],"PHASE1","PHASE2","The goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to answer are:\n\n1. Does small extracellular vesicles combined with traditional drug treatment improve hearing even better in severe and above sudden deafness participants?\n2. What medical problems do participants have with intratympanic injection of small extracellular vesicles? Researchers will compare small extracellular vesicles to dexamethasone to see if small extracellular vesicles work to treat severe and above sudden sensorineural hearing loss.\n\nIn clinical Phase I trial, the investigators will complete the safety check and dose exploration.\n\nParticipants will:\n\n1. Receive traditional drug treatment in accordance with the \"Guidelines for the Diagnosis and Treatment of Sudden Deafness (2015)\n2. Receive small extracellular vesicles or a placebo tympanic injection additionally\n3. Visit the clinic once every 2 weeks for checkups and tests\n4. Receive tympanic injections of small extracellular vesicles ranging from low concentration to high concentration\n5. Be evaluated for any adverse reactions In clinical Phase II trial, participants were randomly divided into a control group and an experimental group.\n\n   Participants will:\n6. Received intratympanic injections of small extracellular vesicles 3 times together with traditional drug treatment in experimental group\n7. Received intratympanic injections of 5mg dexamethasone 3 times together with traditional drug treatment in control group, also for a total of 3 times Visit the clinic once 7 days , 1month and 3 months after treatment for checkups and tests of pure tone audiometry, speech audiometry, tinnitus disability scale and visual analogue scale assessment",[60,29],"Sudden Hearing Loss","NOT_YET_RECRUITING","2026-03-21",{"date":64,"type":36},"2026-03-25",{"date":66,"type":22},"2026-02-28",{"date":68,"type":22},"2028-12-31",{"name":70,"class":43},"The Affiliated Hospital of Qingdao University",5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":80,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":44},"100613980","characterization-of-extracellular-vesicles-from-the-cord-blood-of-extremely-preterm-new-borns-and-their-correlation-with-severe-morbidity-and-mortality-100613980","NCT07273643","Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality","VEEP","Inclusion Criteria:\n\n* Mother over 18 years old, able to speak and understand French\n* Newborn less than 28 weeks of gestation, born and hospitalized at Montpellier University Hospital\n* Umbilical cord venous blood collected immediately after birth (from the segment between the cord clamp and the placenta), with a volume of 10 ml (which can be reduced to 3 ml if collection is difficult) into an EDTA tube.\n* Parental non-opposition to the study obtained before sample collection\n\nExclusion Criteria:\n\n* Stillborn infant\n* Handling failure: failure to collect the sample or start the first centrifugation more than 3 hours after birth\n* General regulatory criteria: failure to obtain parental non-opposition, lack of social security coverage, individuals under legal guardianship, or participation in another ongoing research study with an active exclusion period","0 Days","3 Months",{"count":82,"type":22},30,"OBSERVATIONAL","This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny particles released by cells that carry important information about the body's condition. In extremely premature infants, blood vessels may not function properly, leading to serious health problems such as bleeding in the brain, lung injury, or severe infections.\n\nResearchers believe that analyzing EVs in the umbilical cord blood of these infants may help predict which babies are at higher risk of developing these complications. By studying the size, number, and type of EVs, the team hopes to identify early markers that can guide doctors in providing better care.\n\nThe study will collect cord blood from 30 eligible infants born at the CHU of Montpellier. Blood samples will be processed to isolate platelet-poor plasma, which contains EVs. This plasma will be stored in a biobank, allowing future research on EVs and their role in extreme prematurity. EVs will then be analyzed in the laboratory to assess their characteristics and any links to severe health issues.\n\nThe findings from this study could improve understanding of circulatory problems in extremely premature infants, help identify early predictors of severe complications, and inform better monitoring and treatment strategies. The creation of a plasma biobank also provides a valuable resource for future research to enhance care and outcomes for this vulnerable population.",[86,87,88,89,90,91,29,92],"Intraventricular Hemorrhage","Pulmonary Hemorrhage","Death","ELGAN (22-28SA)","Bronchopulmonary Dysplasia (BPD)","Shock","Enterocolitis, Necrotizing",[94,95,96,97,98,99,100],"ELGAN","Extremely Low Gestational Age Newborn (ELGAN)","Extracellular vesicles","EVs","Intraventricular hemorrage","Pulmonary hemorrhage","Bronchopulmonary Dysplasia","2026-02-19",{"date":103,"type":36},"2026-02-23",{"date":105,"type":36},"2026-01-13",{"date":107,"type":22},"2027-10-13",{"name":109,"class":43},"University Hospital, Montpellier",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":116,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":44},"100604343","characterization-of-evs-extracellular-vesiclesmirnas-micrornas-from-human-follicular-fluid-100604343","NCT07148284","Characterization of EVs (Extracellular Vesicles)\u002FmiRNAs (microRNAs) From Human Follicular Fluid","Inclusion Criteria:\n\n* Signed informed consent.\n* Oocyte retrieval planned for an coPGT-M ICSI trajectory at Ghent University Hospital.\n* BMI 18,5-30 kg\u002Fm2.\n* Normal karyotype of patient and partner.\n* Ovarian stimulation protocol: PPOS (progestin-primed ovarian stimulation) with recombinant gonadotropins and GnRH agonist trigger.\n* A minimum of 5 growing follicles during ovarian stimulation.\n\nExclusion Criteria:\n\n* Diagnosis of endometriosis\n* Diagnosis of PCOS according to Rotterdam criteria\n* Poor ovarian responders according to Bologna criteria\n* Severe male subfertility: semen concentration \\\u003C 5 million\u002Fml or TESE","FEMALE","45 Years",{"count":119,"type":22},14,[25],"* Background Extracellular vesicles (EVs) are membrane-bound vesicles found in all biological fluids. They contain various regulatory molecules, including microRNAs (miRNAs). It is hypothesized that EVs in human follicular fluid (the fluid surrounding the oocyte within the ovary) play a crucial role in oocyte development through these miRNAs.\n* Research Question Is there a difference in miRNA expression in EVs in human follicular fluid based on the patient's age, the maturation stage of the corresponding oocyte, and\u002For the ploidy status of the resulting embryo (euploid in the case of a normal chromosome count vs. aneuploid in the case of an abnormal chromosome count)?\n* Methodology This prospective study will include patients in two age groups (≥ 38 years vs. ≤ 32 years; 7 patients per group) undergoing an ICSI treatment (intracytoplasmic sperm injection) in combination with a coPGT-M treatment at Ghent University Hospital. PGT-M (pre-implantation genetic testing for monogenic disorders) is an IVF\u002FICSI procedure in which an embryo biopsy is performed on day 5 or 6 of embryo development to test for known genetic disorders that could be inherited from one or both parents. With the coPGT-M technology or comprehensive PGT-M, in addition to detecting known genetic defects, any additional chromosomal abnormalities in the embryo are also identified. An embryo is considered aneuploid if its chromosome number is abnormal.\n\nFor the participating patients, follicular fluid and plasma will be collected, and consent will be requested to store non-developing oocytes and embryos from the ICSI treatment.\n\nInclusion will take place on day 10 of ovarian stimulation if the patient meets the inclusion and exclusion criteria and at least 5 follicles are confirmed to be growing.\n\n* Follicular Fluid (residual material): After oocyte retrieval, follicular fluid will be collected from 2-10 follicles per patient. EV isolation from this follicular fluid will be performed using the optimal technique determined in a preceding experiment (ID 18220, see 'Relations', comparison of 3 existing techniques to determine the optimal EV isolation technique from human follicular fluid). RNA extraction followed by miRNA sequencing will be used to assess differences in miRNA expression based on age (≤ 32 years vs. ≥ 38 years), oocyte maturation stage (mature vs. immature), and the ploidy status of the resulting embryo (euploid vs. aneuploid). In addition, the following hormone concentrations will be determined in the follicular fluid: estradiol, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH).\n* Plasma: For participating patients, an additional blood tube will be taken during each blood sample\u002Finfusion placement within the standard-of-care IVF\u002FICSI treatment from day 10 of ovarian stimulation until the day of oocyte retrieval. EV isolation and RNA extraction will be performed on plasma samples of the ovulation trigger day and oocyte retrieval day. MiRNA sequencing of these samples will be correlated with the miRNA expression of EVs in follicular fluid.",[29],[96,124],"RNA sequencing","2025-08-22",{"date":127,"type":36},"2025-08-29",{"date":129,"type":22},"2025-09",{"date":131,"type":22},"2025-12",{"name":133,"class":43},"University Hospital, Ghent",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":83,"phases":4,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100487318","exoluminate-study-for-early-detection-of-pancreatic-cancer-100487318","NCT05625529","ExoLuminate Study for Early Detection of Pancreatic Cancer","Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients","Inclusion Criteria:\n\n* ≥18 years old.\n* Meeting criteria for one of the study cohorts.\n* Capable of giving informed consent.\n* Able to provide a blood sample.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old.\n* Pregnancy.\n* Active cancer (other than pancreatic cancer) and\u002For undergoing treatment for an active cancer diagnosis (except for skin malignancies).\n* Prior organ transplant or bone marrow transplant.\n* History of fainting or other adverse effects when blood is drawn.\n* Any condition that, in the opinion of the investigator, should preclude enrollment.",{"count":142,"type":22},1000,"3 Years","ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).\n\nThose with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.\n\nThe goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.",[146,147,29,148],"Pancreas Cancer","Exosomes","Pancreatic Neoplasms",[150,147,29,151,152,153],"Early Detection","IPMN","PDAC","Pancreatic Cancer","2025-07-24",{"date":156,"type":36},"2025-07-28",{"date":158,"type":36},"2022-12-19",{"date":160,"type":22},"2028-01-01",{"name":162,"class":163},"Biological Dynamics","INDUSTRY",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":44},"100579536","phase-1-msc-evs-in-acute-acute-on-chronic-liver-failure-after-liver-transplantation-100579536","NCT06825572","MSC-EVs in Acute\u002F Acute-on-Chronic Liver Failure After Liver Transplantation","Mesenchymal Stem Cells-Derived Extracellular Vesicles (MSC-EV) in Acute\u002FAcute-on-Chronic Liver Failure After Liver Transplantationa：a Prospective, Randomized, Controlled Clinical Study","Inclusion Criteria:\n\n* aged 18-70 years;\n* Acute on chronic liver failure-which is characterized by acute hepatic insult manifesting as jaundice (serum total bilirubin \\[TBil\\] ≥ 10×ULN umol\u002FL) and coagulopathy (international normalized ratio \\[INR\\] ≥ 1.5 or prothrombin activity \\\u003C 40%), complicated within 4 weeks by ascites and\u002For encephalopathy as determined by physical examination, in patients with previously diagnosed or undiagnosed chronic liver disease; Requiring liver transplantation due to acute on chronic liver failure;\n* Obtain the patients' consent after informing patients of the purpose and method of the clinical trial;\n\nExclusion Criteria:\n\n* Past history of malignant disease\n* Active uncontrolled infection;\n* Combined transplantation\n* EBV-negative;\n* HIV or HCV positive;\n* Retransplantation;","70 Years",{"count":82,"type":22},[56],"Acute liver failure (ALF) refers to a potentially reversible disorder that was the result of severe liver injury, with an onset of encephalopathy within 8 weeks of symptom appearance and in the absence of pre-existing liver disease. Acute-on-chronic liver failure refers to a liver failure syndrome in which some patients with chronic liver disease with relatively stable liver function suffer from acute liver decompensation and liver failure due to the effects of various acute injury factors. Liver transplantation is the only curative treatment for this type of end-stage liver disease. The potential of MSCs to repair or regenerate damaged tissue and suppress immune responses makes them promising in the treatment of liver diseases, especially in the field of liver transplantation. Many studies have shown that MSC-based therapies can reduce the symptoms of liver disease due to their paracrine effects. Therefore, compared to the cells they derive from, mesenchymal stem cells-derived extracellular vesicles (MSC-EV) are gradually gaining attention for their enhanced safety, as they do not replicate or cause microvascular embolism, and can be easily stored without losing their properties. It represents a novel and effective cell-free therapeutic agent as alternative to cell-based therapies for liver diseases, and liver failure was also concerned. This study was designed to evaluate the safety and tolerability of MSC-EV in acute-on-chronic liver failure after liver transplantation.",[176,177,29],"Liver Failure","Mesenchymal Stem Cell",[179,180,181],"MSC-EV","Liver transplantation","Liver failure","2025-02-09",{"date":184,"type":36},"2025-02-13",{"date":186,"type":22},"2025-04-01",{"date":188,"type":22},"2026-09-30",{"name":190,"class":43},"Third Affiliated Hospital, Sun Yat-Sen University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":44},"100558732","study-of-extracellular-vesicles-ev-in-patients-undergoing-car-t-cell-therapies-100558732","NCT06554951","Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies","Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapy","Inclusion Criteria:\n\n* patients affeccted by any hematological malignancies (r\u002Fr B cell lymphoma, B cell acute leukemia and multiple myeloma) undergoing (or whit indication to) CAR-T cell infusion with a CAR-T cell product;\n* age: 18 years or greater;\n* obtained written consent to the study participation.\n\nExclusion Criteria:\n\n* none","90 Years",{"count":200,"type":22},100,"Patients with refractory\u002Frelapse hematologic oncology disease may benefit from innovative therapy such as Car-T cells. Factors strongly predictive of outcome and response are unknown. Extracellular vesicles are recognized as a mode of intercellular communication and are reminiscent of the cell of origin. They are currently candidates to be biomarkers for this biomarker of phenomena occurring in tissues. The working hypothesis is that they may be predictive of outcome and toxicity, as some preliminary data have suggested.\n\nTherefore, the aim of the study concerns I dentification of potential CAR-EV biomarkers associated with neurological toxicity after infusion of CAR-T cells.",[203,29],"CAR-T Cell Therapy","2024-12-20",{"date":206,"type":36},"2024-12-27",{"date":208,"type":36},"2024-08-31",{"date":210,"type":22},"2026-08-31",{"name":212,"class":43},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]